Emerging therapeutic potential of graviola and its constituents in cancers

Asif Khurshid Qazi, Jawed A. Siddiqui, Rahat Jahan, Sanjib Chaudhary, Larry A. Walker, Zafar Sayed, Dwight T Jones, Surinder Kumar Batra, Muzafar A Macha

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Cancer remains a leading cause of death in the USA and around the world. Although the current synthetic inhibitors used in targeted therapies have improved patient prognosis, toxicity and development of resistance to these agents remain a challenge. Plant-derived natural products and their derivatives have historically been used to treat various diseases, including cancer. Several leading chemotherapeutic agents are directly or indirectly based on botanical natural products. Beyond these important drugs, however, a number of crude herbal or botanical preparations have also shown promising utility for cancer and other disorders. One such natural resource is derived from certain plants of the family Annonaceae, which are widely distributed in tropical and subtropical regions. Among the best known of these is Annona muricata, also known as soursop, graviola or guanabana. Extracts from the fruit, bark, seeds, roots and leaves of graviola, along with several other Annonaceous species, have been extensively investigated for anticancer, anti-inflammatory and antioxidant properties. Phytochemical studies have identified the acetogenins, a class of bioactive polyketide-derived constituents, from the extracts of Annonaceous species, and dozens of these compounds are present in different parts of graviola. This review summarizes current literature on the therapeutic potential and molecular mechanism of these constituents from A.muricata against cancer and many non-malignant diseases. Based on available data, there is good evidence that these long-used plants could have both chemopreventive and therapeutic potential. Appropriate attention to safety studies will be important to assess their effectiveness on various diseases caused or promoted by inflammation.

Original languageEnglish (US)
Pages (from-to)522-533
Number of pages12
JournalCarcinogenesis
Volume39
Issue number4
DOIs
StatePublished - Apr 5 2018

Fingerprint

Annona
Biological Products
Neoplasms
Acetogenins
Annonaceae
Polyketides
Cotyledon
Phytochemicals
Therapeutics
Cause of Death
Fruit
Anti-Inflammatory Agents
Antioxidants
Inflammation
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research

Cite this

Qazi, A. K., Siddiqui, J. A., Jahan, R., Chaudhary, S., Walker, L. A., Sayed, Z., ... Macha, M. A. (2018). Emerging therapeutic potential of graviola and its constituents in cancers. Carcinogenesis, 39(4), 522-533. https://doi.org/10.1093/carcin/bgy024

Emerging therapeutic potential of graviola and its constituents in cancers. / Qazi, Asif Khurshid; Siddiqui, Jawed A.; Jahan, Rahat; Chaudhary, Sanjib; Walker, Larry A.; Sayed, Zafar; Jones, Dwight T; Batra, Surinder Kumar; Macha, Muzafar A.

In: Carcinogenesis, Vol. 39, No. 4, 05.04.2018, p. 522-533.

Research output: Contribution to journalReview article

Qazi, AK, Siddiqui, JA, Jahan, R, Chaudhary, S, Walker, LA, Sayed, Z, Jones, DT, Batra, SK & Macha, MA 2018, 'Emerging therapeutic potential of graviola and its constituents in cancers', Carcinogenesis, vol. 39, no. 4, pp. 522-533. https://doi.org/10.1093/carcin/bgy024
Qazi AK, Siddiqui JA, Jahan R, Chaudhary S, Walker LA, Sayed Z et al. Emerging therapeutic potential of graviola and its constituents in cancers. Carcinogenesis. 2018 Apr 5;39(4):522-533. https://doi.org/10.1093/carcin/bgy024
Qazi, Asif Khurshid ; Siddiqui, Jawed A. ; Jahan, Rahat ; Chaudhary, Sanjib ; Walker, Larry A. ; Sayed, Zafar ; Jones, Dwight T ; Batra, Surinder Kumar ; Macha, Muzafar A. / Emerging therapeutic potential of graviola and its constituents in cancers. In: Carcinogenesis. 2018 ; Vol. 39, No. 4. pp. 522-533.
@article{4a74134ac68342aaad21e2b84c36d00b,
title = "Emerging therapeutic potential of graviola and its constituents in cancers",
abstract = "Cancer remains a leading cause of death in the USA and around the world. Although the current synthetic inhibitors used in targeted therapies have improved patient prognosis, toxicity and development of resistance to these agents remain a challenge. Plant-derived natural products and their derivatives have historically been used to treat various diseases, including cancer. Several leading chemotherapeutic agents are directly or indirectly based on botanical natural products. Beyond these important drugs, however, a number of crude herbal or botanical preparations have also shown promising utility for cancer and other disorders. One such natural resource is derived from certain plants of the family Annonaceae, which are widely distributed in tropical and subtropical regions. Among the best known of these is Annona muricata, also known as soursop, graviola or guanabana. Extracts from the fruit, bark, seeds, roots and leaves of graviola, along with several other Annonaceous species, have been extensively investigated for anticancer, anti-inflammatory and antioxidant properties. Phytochemical studies have identified the acetogenins, a class of bioactive polyketide-derived constituents, from the extracts of Annonaceous species, and dozens of these compounds are present in different parts of graviola. This review summarizes current literature on the therapeutic potential and molecular mechanism of these constituents from A.muricata against cancer and many non-malignant diseases. Based on available data, there is good evidence that these long-used plants could have both chemopreventive and therapeutic potential. Appropriate attention to safety studies will be important to assess their effectiveness on various diseases caused or promoted by inflammation.",
author = "Qazi, {Asif Khurshid} and Siddiqui, {Jawed A.} and Rahat Jahan and Sanjib Chaudhary and Walker, {Larry A.} and Zafar Sayed and Jones, {Dwight T} and Batra, {Surinder Kumar} and Macha, {Muzafar A}",
year = "2018",
month = "4",
day = "5",
doi = "10.1093/carcin/bgy024",
language = "English (US)",
volume = "39",
pages = "522--533",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Emerging therapeutic potential of graviola and its constituents in cancers

AU - Qazi, Asif Khurshid

AU - Siddiqui, Jawed A.

AU - Jahan, Rahat

AU - Chaudhary, Sanjib

AU - Walker, Larry A.

AU - Sayed, Zafar

AU - Jones, Dwight T

AU - Batra, Surinder Kumar

AU - Macha, Muzafar A

PY - 2018/4/5

Y1 - 2018/4/5

N2 - Cancer remains a leading cause of death in the USA and around the world. Although the current synthetic inhibitors used in targeted therapies have improved patient prognosis, toxicity and development of resistance to these agents remain a challenge. Plant-derived natural products and their derivatives have historically been used to treat various diseases, including cancer. Several leading chemotherapeutic agents are directly or indirectly based on botanical natural products. Beyond these important drugs, however, a number of crude herbal or botanical preparations have also shown promising utility for cancer and other disorders. One such natural resource is derived from certain plants of the family Annonaceae, which are widely distributed in tropical and subtropical regions. Among the best known of these is Annona muricata, also known as soursop, graviola or guanabana. Extracts from the fruit, bark, seeds, roots and leaves of graviola, along with several other Annonaceous species, have been extensively investigated for anticancer, anti-inflammatory and antioxidant properties. Phytochemical studies have identified the acetogenins, a class of bioactive polyketide-derived constituents, from the extracts of Annonaceous species, and dozens of these compounds are present in different parts of graviola. This review summarizes current literature on the therapeutic potential and molecular mechanism of these constituents from A.muricata against cancer and many non-malignant diseases. Based on available data, there is good evidence that these long-used plants could have both chemopreventive and therapeutic potential. Appropriate attention to safety studies will be important to assess their effectiveness on various diseases caused or promoted by inflammation.

AB - Cancer remains a leading cause of death in the USA and around the world. Although the current synthetic inhibitors used in targeted therapies have improved patient prognosis, toxicity and development of resistance to these agents remain a challenge. Plant-derived natural products and their derivatives have historically been used to treat various diseases, including cancer. Several leading chemotherapeutic agents are directly or indirectly based on botanical natural products. Beyond these important drugs, however, a number of crude herbal or botanical preparations have also shown promising utility for cancer and other disorders. One such natural resource is derived from certain plants of the family Annonaceae, which are widely distributed in tropical and subtropical regions. Among the best known of these is Annona muricata, also known as soursop, graviola or guanabana. Extracts from the fruit, bark, seeds, roots and leaves of graviola, along with several other Annonaceous species, have been extensively investigated for anticancer, anti-inflammatory and antioxidant properties. Phytochemical studies have identified the acetogenins, a class of bioactive polyketide-derived constituents, from the extracts of Annonaceous species, and dozens of these compounds are present in different parts of graviola. This review summarizes current literature on the therapeutic potential and molecular mechanism of these constituents from A.muricata against cancer and many non-malignant diseases. Based on available data, there is good evidence that these long-used plants could have both chemopreventive and therapeutic potential. Appropriate attention to safety studies will be important to assess their effectiveness on various diseases caused or promoted by inflammation.

UR - http://www.scopus.com/inward/record.url?scp=85045203890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045203890&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgy024

DO - 10.1093/carcin/bgy024

M3 - Review article

VL - 39

SP - 522

EP - 533

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 4

ER -